interview
Inside Biotech podcast (E34): Michael Heltzen interview
Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is...
interview
The challenges of SynBio - by Zachary Karl, PhD
“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a...
Heltzen's updates
Thank you, MDB Capital
A big shoutout to MDB Capital for last week’s investor conference in Dallas, Texas!
Webinars
eXoZymes second quarter 2025 update
eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform...
investors
NCT: Damien on 4 grams of NCT with over 99% purity
🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a...
investors
NCT: From concept to gram-scale quantity in only 5 months
🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone...
interview
Slack Capital interview: Chris Marlett, Chairman of the...
Last week, Slack Capital - an Australian investment research publication - released an investment...
interview
Slack Capital interview: Chris Marlett, Chairman of the...
Last week, Slack Capital - an Australian investment research publication - released an investment...
investors
Slack Capital interview: Damien Perriman, CCO
Last week, Slack Capital - an Australian investment research publication - has released an...
investors
Slack Capital interview: Damien Perriman, CCO (teaser)
Last week, Slack Capital - an Australian investment research publication - has released an...
Webinars
eXoZymes first quarter 2025 and subsidiary NCTx update
eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform...
investors
Slack Capital interview: Tyler Korman, VP of Research
This week, Slack Capital - an Australian investment research publication - has released an...